BTG Plc – Strategy, SWOT and Corporate Finance Report

BTG Plc – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.

BTG plc (BTG) develops, manufactures and sells medicines for acute care, cancer and vascular diseases. The company develops specialty drugs including antidotes for snake envenomation and toxicity related to medicines used for heart conditions and cancer; interventional vascular products for treating patients with severe blood clots and varicose veins; and interventional cancer products for treating patients with liver tumors and emphysema. The company develops products and acquires or in-licenses from other companies. BTG markets its products either directly or through distribution agreements. The company operates along with its subsidiaries in the US, Europe and Asia. BTG is headquartered in London, England, the UK.

Scope

Detailed information on BTG Plc required for business and competitor intelligence needs

A study of the major internal and external factors affecting BTG Plc in the form of a SWOT analysis

An in-depth view of the business model of BTG Plc including a breakdown and examination of key business segments

News about BTG Plc, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of BTG Plc and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess BTG Plc as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on BTG Plcs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Transgene SA

Sirtex Medical Ltd

Merit Medical Systems Inc

Immupharma Plc

F. Hoffmann-La Roche Ltd

CeloNova BioSciences Inc

Baxter International Inc

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 - About the Company 6

BTG Plc - Key Facts 6

BTG Plc - Key Employees 7

BTG Plc - Key Employee Biographies 8

BTG Plc - Major Products and Services 9

BTG Plc - History 10

BTG Plc - Company Statement 14

BTG Plc - Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2 Company Analysis 18

Company Overview 18

BTG Plc - Business Description 19

Business Segment: Interventional Medicine 19

Overview 19

Performance 19

Business Segment: Licensing 19

Overview 19

Performance 19

Business Segment: Pharmaceuticals 19

Overview 19

Performance 20

Geographical Segment: Europe 20

Performance 20

Geographical Segment: Other Regions 20

Performance 20

Geographical Segment: USA 20

Performance 20

R&D Overview 20

BTG Plc - Corporate Strategy 21

BTG Plc - SWOT Analysis 22

SWOT Analysis - Overview 22

BTG Plc - Strengths 22

BTG Plc - Weaknesses 23

BTG Plc - Opportunities 24

BTG Plc - Threats 25

BTG Plc - Key Competitors 26

Section 3 Company Financial Ratios 27

Financial Ratios - Capital Market Ratios 27

Financial Ratios - Annual Ratios 28

Performance Chart 31

Financial Performance 31

Financial Ratios - Interim Ratios 32

Financial Ratios - Ratio Charts 33

Section 4 Company’s Lifesciences Financial Deals and Alliances 34

BTG Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 34

BTG Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 35

BTG Plc, Recent Deals Summary 36

Section 5 Company’s Recent Developments 37

Sep 11, 2018: BTG buys vascular devices firm Novate Medical 37

Jun 21, 2018: PERT Consortium and BTG Form Strategic Partnership 38

May 15, 2018: BTG: Final Results For year ended 31 March 2018 39

Apr 04, 2018: SIO and BTG Announce Recipients of Immuno-Oncology/Interventional Oncology Grant Program 45

Nov 27, 2017: BTG Announced the Appointment of Non-executive Director 47

Nov 14, 2017: BTG: Directorate change - Chief Financial Officer 48

Nov 14, 2017: BTG: Interim Results 49

Sep 13, 2017: Vistogard and Voraxaze Added to Revised Guidelines for Stocking of Antidotes in US Hospitals 55

Aug 21, 2017: BTG and SIO Expand Immuno-Oncology / Interventional Oncology Grant Programme 56

Jun 16, 2017: ACCESS PTS Study Demonstrates Efficacy of EKOS® Therapy for Post-Thrombotic Syndrome 57

Section 6 Appendix 58

Methodology 58

Ratio Definitions 58

About GlobalData 62

Contact Us 62

Disclaimer 62

List of Tables

List of Tables

BTG Plc, Key Facts 6

BTG Plc, Key Employees 7

BTG Plc, Key Employee Biographies 8

BTG Plc, Major Products and Services 9

BTG Plc, History 10

BTG Plc, Subsidiaries 15

BTG Plc, Key Competitors 26

BTG Plc, Ratios based on current share price 27

BTG Plc, Annual Ratios 28

BTG Plc, Annual Ratios (Cont…1) 29

BTG Plc, Annual Ratios (Cont…2) 30

BTG Plc, Interim Ratios 32

BTG Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 34

BTG Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 35

BTG Plc, Recent Deals Summary 36

Currency Codes 58

Capital Market Ratios 58

Equity Ratios 59

Profitability Ratios 59

Cost Ratios 60

Liquidity Ratios 60

Leverage Ratios 61

Efficiency Ratios 61

List of Figures

List of Figures

BTG Plc, Performance Chart (2014 – 2018) 31

BTG Plc, Ratio Charts 33

BTG Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 34

BTG Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 35

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports